Gabapentin treatment of neurogenic overactive bladder

Clinical Neuropharmacology

Volumn 29, Issue 4, 2006, Pages 206-214

  Carbone, Antonio ^a   Palleschi, Giovanni ^a   Conte, Antonella ^b   Bova, Gino ^a   Iacovelli, Elisa ^b   Bettolo, Chiara Marini ^b   Pastore, Antonio ^a,c   Inghilleri, Maurizio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c NONE   (Italy)

Author keywords

Gabapentin; Neurogenic detrusor overactivity; Treatment of neurogenic overactive bladder

Indexed keywords

GABAPENTIN; 4 AMINOBUTYRIC ACID; AMINE; ANTICONVULSIVE AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIZZINESS; DRUG EFFICACY; HUMAN; MICTURITION; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PRIORITY JOURNAL; SCORING SYSTEM; SOMNOLENCE; TREATMENT OUTCOME; URODYNAMICS; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; AMINES; ANTICONVULSANTS; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; URINARY BLADDER, NEUROGENIC;

EID: 33748753867     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WNF.0000228174.08885.AB     Document Type: Article

References (40)

1. Abrams P, Wein A. The Overactive Bladder: A Widespread and Treatable Condition. Stockholm: Erik Sparre Medical AB; 1998.
2. Jackson S. The patient with overactive bladder - symptoms and quality of life issues. Urology 1997;50(6A suppl):18-22.
3. Johannesson M, O'Connor RM, Kobelt G, et al. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997;80:557-562.
4. Kobelt G, Kirchberger I, Malone-Lee J. Review. Quality of life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1999;83:583-590.
5. Holroyd-Leduc JM, Mehta KM, Covinsky KE. Urinary incontinence and its association with death, nursing home admission, and functional decline. J Am Geriatr Soc 2004;52(5):712-718.
6. Turner-Warwick R. Observations on the function and dysfunction of the sphyncter and detrusor mechanism. Urol Clin North Am 1979;6:23-29.
7. Abrams P, Wein AJ. The overactive bladder and incontinence: definitions and a plea for discussion. Neurourol Urodyn 1999;18:413-416.
8. Malone-Lee JG. New data on urodynamics in the symptomatic elderly. Neurourol Urodyn 1988;7:119-222.
9. Guay DR. Darifenacin: another antimuscarinic for overactive bladder. Consult Pharm 2005;20(5):424-431.
10. Payne CK. Solifenacin in overactive bladder syndrome. Drugs 2006;66(2):175-190.
11. Zinner NR. Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder. Expert Opin Pharmacother 2005;6(8):1409-1420.
12. Andersson K-E. Advances in the pharmacological control of the bladder. Exp Physiol 1999;84(1):195-213.
13. Chancellor MB, de Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 1999;162:3.
14. Dasgupta P, Chandrimani VA, Beckett A, et al. The effect of intravesical capsaicin on the suburothelial innervation in patients with detrusor hyper-reflexia. BJU Int 2000;85(3):238-245.
15. Klingler HC, Pycha A, Schmidbauer J, et al. Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study. Urology 2000;56(5):766-771.
16. Caviedes BE, Henanz JL. Use of antiepileptic drugs in non epileptic disorders. Rev Neurol 2000;33(3):241-249.
17. Taylor CP. Mechanisms of action of gabapentin. Rev Neurol (Paris) 1997;153(suppl 1):s39-s45.
18. Sasaki K, Smith CP, Chuang YC, et al. Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. Tech Urol 2001;7(1):47-49.
19. Gu LY, Huang Y. Gabapentin actions on N-methyl-D-aspartate receptor channels are protein kinase C-dependent. Pain 2001;93(1):85-92.
20. Marais E, Klugbauer N, Hofmann F. Calcium channel alpha(2)delta subunits-structure and gabapentin binding. Mol Pharmacol 2001;59(5):1243-1248.
21. Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K(+)-evoked release of (3H)glutamate from rat caudial trigeminal nucleus slices. Pain 2001;93(2):191-196.
22. Hwang JH, Yaksh TL. Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically induced neuropathic pain model in the rat. Reg Anesth 1997;22(3):249-256.
23. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction 3. Detrusor overactivity. J Urol 1993a;150:1668-1680.
24. Barrington FJF. The component reflexes of micturition in the cat, parts I and II. Brain 1931;54:177.
25. Mahoni DT, Laferte RO, Blais DJ. Integral storage and voiding reflexes. Urology 1977;9:95.
26. Bulmer P, Abrams P. The overactive bladder. Rev Contemp Pharmacother 2000;11:1-11.
27. Mallory BS, Roppolo JR, de Groat WC. Pharmacological modulation of the pontine micturition centre. Brain Res 1991;546:310-320.
28. de Groat WC, Booth AM, Yoshimura N. Neurophysiology of micturition and its modification in animal models of human disease. In: Maggi CA, ed. The Autonomic Nervous System, Vol 3. Nervous Control of the Urogenital System. London: Harwood Academic Publishers; 1993:222-290.
29. Van Arsdalen K, Wein AJ. Physiology of micturition and continence. In: Krane RD, Siroky M, eds. Clinical Neuro-urology. New York: Little Brown; 1991:25-82.
30. de Groat WC. Nervous control of the urinary bladder of the cat. Brain Res 1975;87:201-211.
31. Torrens MJ, Morrison JFB. The physiology of lower urinary tract. Berlin: Springer-Verlag; 1987.
32. Block BFM, Willemsen ATM, Holstege G. A PET study on the brain control of micturition in humans. Brain 1997;20:111-121.
33. Formica A, Verger K, Sol JM, et al. Gabapentin for spasticity: a randomized, double-blind, placebo-controlled trial. Med Clin (Barc) 2005;124(3):81-85.
34. Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs 2000;59(3):487-495.
35. Stocchi F, Carbone A, Inghilleri M, et al. Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 1997;62(5):507-511.
36. Fingerman JS, Finkelstein LH. The overactive bladder in multiple sclerosis. J Am Osteopath Assoc 2000;100(3 suppl):S9-S12.
37. Ciancio SJ, Mutchnik SE, Rivera VM, et al. Urodynamic pattern changes in multiple sclerosis. Urology 2001;57(2):239-245.
38. Stanfa LC, Singh L, Williams RG, et al. Gabapentin, ineffective in normal rats, markedly reduces C evoked responses after inflammation. Neuroreport 1997;8(3):587-590.
39. Bayer K, Ahmadi S, Zeilhofer HU. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P/Q-type Ca2+ channels. Neuropharmacology 2004;46(5):743-749.
40. Fowler CJ. Bladder afferents and their role in the overactive bladder. Urology 2002;59(5 suppl 1):37-42.